Search hospitals > Ohio > Springfield
Springfield Regional Cancer Center
Claim this profileSpringfield, Ohio 45504
Global Leader in Cancer
Global Leader in Breast Cancer
Conducts research for Lung Cancer
Conducts research for Non-Small Cell Lung Cancer
Conducts research for Adenocarcinoma
203 reported clinical trials
2 medical researchers
Summary
Springfield Regional Cancer Center is a medical facility located in Springfield, Ohio. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Springfield Regional Cancer Center is involved with conducting 203 clinical trials across 391 conditions. There are 2 research doctors associated with this hospital, such as Timothy D. Moore and Howard M. Gross.Area of expertise
1Cancer
Global LeaderStage IV
Stage III
Stage II
2Breast Cancer
Global LeaderStage IV
HER2 negative
ER positive
Top PIs
Timothy D. MooreThe Mark H Zangmeister Center4 years of reported clinical research
Expert in Cancer
Expert in Lung Cancer
126 reported clinical trials
208 drugs studied
Howard M. GrossDayton Physician LLC-Miami Valley Hospital North4 years of reported clinical research
Expert in Cancer
Expert in Breast Cancer
128 reported clinical trials
194 drugs studied
Clinical Trials running at Springfield Regional Cancer Center
Breast Cancer
Non-Small Cell Lung Cancer
Lung Cancer
Cancer
Bladder Cancer
Bladder Carcinoma
Melanoma
Cutaneous Melanoma
Gastric Cancer
Renal Cell Carcinoma
Support Program
for Breast Cancer
This phase III trial compares an additional support program (text message reminders and/or telephone-based counseling) with usual care in making sure breast cancer patients take their endocrine therapy medication as prescribed (medication adherence). Medication adherence is how well patients take the medication as prescribed by their doctors, and good medical adherence is when patients take medications correctly. Poor medication adherence has been shown to be a serious barrier to effective treatment for hormone receptor positive breast cancer patients. Adding text message reminders and/or telephone-based counseling to usual care may increase the number of days that patients take their endocrine therapy medication as prescribed.
Recruiting2 awards Phase 34 criteria
Carvedilol
for Preventing Heart Problems in HER2 Positive Breast Cancer
This phase III trial studies how well carvedilol works in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may prevent the heart from side effects of chemotherapy.
Recruiting2 awards Phase 323 criteria
Pembrolizumab
for Triple-Negative Breast Cancer
The phase III trial compares the effect of pembrolizumab to observation for the treatment of patients with early-stage triple-negative breast cancer who achieved a pathologic complete response after preoperative chemotherapy in combination with pembrolizumab. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial may help researchers determine if observation will result in the same risk of cancer coming back as pembrolizumab after surgery in triple-negative breast cancer patients who achieve pathologic complete response after preoperative chemotherapy with pembrolizumab.
Recruiting2 awards Phase 319 criteria
Similar Hospitals nearby
Frequently asked questions
What kind of research happens at Springfield Regional Cancer Center?
Springfield Regional Cancer Center is a medical facility located in Springfield, Ohio. This center is recognized for care of Cancer, Breast Cancer, Lung Cancer, Non-Small Cell Lung Cancer, Adenocarcinoma and other specialties. Springfield Regional Cancer Center is involved with conducting 203 clinical trials across 391 conditions. There are 2 research doctors associated with this hospital, such as Timothy D. Moore and Howard M. Gross.